Literature DB >> 29937337

Excess Cost and Healthcare Resources Associated With Delayed Diagnosis of Charcot Foot.

Jonathan M Labovitz1, Jarrod M Shapiro2, V Kathleen Satterfield3, Nathanael T Smith4.   

Abstract

The purpose of the present study was to demonstrate the effect of a delayed diagnosis of Charcot foot on acute care cost and usage. We used International Classification of Disease, Ninth Revision, Clinical Modification codes, and the California Office for Statewide Health Planning and Development 2009 to 2012 public patient discharge files to identify patients with type 2 diabetes mellitus and Charcot foot. The costs and length of stay were compared for those with a diagnosis of Charcot foot on admission compared with those who received a delayed diagnosis of Charcot foot before discharge. Patient demographic data, diagnoses often mistaken for Charcot foot, and procedures often performed for Charcot foot were assessed to determine the potential effect on costs and length of stay in Charcot foot subjects. A delayed Charcot foot diagnosis was associated with 10.8% greater inpatient costs and 12.1% longer length of stay. These patients required greater resource usage owing to the significantly greater number of procedures performed. A significantly greater number of patients underwent lower extremity amputation when the diagnosis was delayed, resulting in a 30.4% increase in costs and 31.6% longer length of stay. A greater rate of diabetic foot ulcers, foot infections, and osteomyelitis was also observed; however, the cost was only affected by osteomyelitis, and the length of stay was not significantly affected. A delayed diagnosis of Charcot foot at admission resulted in significantly increased acute care costs and longer lengths of stay.
Copyright © 2018 The American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Charcot foot; cost; delayed diagnosis; length of stay

Mesh:

Year:  2018        PMID: 29937337     DOI: 10.1053/j.jfas.2018.03.036

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  3 in total

Review 1.  Updates on Diabetic Foot and Charcot Osteopathic Arthropathy.

Authors:  Brian M Schmidt; Crystal M Holmes
Journal:  Curr Diab Rep       Date:  2018-08-15       Impact factor: 4.810

2.  Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?

Authors:  Rachel H Albright; Robert M Joseph; Dane K Wukich; David G Armstrong; Adam E Fleischer
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

3.  Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Nina L Petrova; Nicholas K Donaldson; Maureen Bates; Wegin Tang; Timothy Jemmott; Victoria Morris; Tracy Dew; Lisa Meacock; David A Elias; Cajetan F Moniz; Michael E Edmonds
Journal:  Diabetes Care       Date:  2021-06-04       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.